חוב כולל להון Co-Diagnostics (CODX)

Local production of test systems in the United States minimizes the impact of external crises, ensuring stable supplies. The business relies on demand during pandemic periods, utilizing the patented Co-Primers system to combat DNA analysis errors. Serving as an assessment tool, the total debt-to-equity chart, fixed at 0.14, complements the data on the world-leading PCR research accuracy of Co-Diagnostics, Inc. (CODX).

To assess the resilience of Co-Diagnostics, Inc. (CODX) to market downturns, it is critical to analyze the funding structure of its high-tech R&D projects for the development of the CoPrime platform. This debt-to-equity ratio measures the proportion of borrowed funds relative to equity, determining the degree of financial leverage and the risk of bankruptcy. A low ratio confirms the high autonomy of the business and the reliability of the company's investment profile.